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Interleukin-6: A Potent Suppressor of Growth of Melanoma In Vivo 
The role of melanoma-derived cytokines in the growth and devel-
opment of melanoma is of increasing interest, because it is hoped 
that these regulatory proteins may be useful in the treatment of 
human cancer. These cytokines might be able to influence the mel-
anoma itself by regulating its growth. In this issue, Armstrong et al 
(p. 278) ~escribe the ab.ility ~f a cytokine derived fro~ m~lano~na, 
interleukm 6 (IL-6), to mhlblt growth of melanomas m mice. Fmt, 
the authors noticed that melanoma cells that produced IL-6 pro-
duced fewer tumors in experiments in mice. To try to determine 
whether the IL-6 might be influencing growth of melanomas in the 
mice, they transfected a murine melanoma cell line with the gene 
for IL-6 and produced cell lines that secreted large amounts of 
biologically active IL-6. Control cells were transfected with the 
IL-6 gene improperly oriented in the viral vector and did not pro-
duce IL-6. When inoculated subcutaneously into syngeneic mice, 
the IL-6 - producing melanoma cells formed tumors that were on 
av.era~e less than h.alf the size of tumors that developed in control 
mice moculated With melanoma cells unable to produce increased 
amounts of IL-6. Also, mice bearing IL-6-producing tumors sur-
vived twice as long as control mice. The investigators found that the 
reduced growth of tumors in mice with IL-6 - producing tumor 
cells was reversed by injection into the tumors of neutralizing anti-
body against IL-6, further supporting the role ofIL-6 in the growth 
of the melanomas. To determine whether the immune system of the 
mouse might be required for these effects ofIL-6, the investigators 
studied nude mice. IL-6 - producing melanomas were also smaller 
in nude mice, indicating that the anti-tumor effect of IL-6 does not 
depend on a normal host B- and T-cell immune response. These 
studies showing that IL-6 inhibits growth of melanoma in mice 
suggest that IL-6 may be useful in the treatment of melanoma in 
humans. 
Ras Mutations in Human Melanoma: An Early or Late Event in Malignant Progression? 
Ras oncogenes were first discovered in oncogenic murine retrovi-
ruses. Harvey sarcoma virus and Kirsten sarcoma virus both cause 
sarcomas in mice and rats and carry mutated forms of H-ras and 
K-ras. A third type, neutroblastoma-ras (N-ras), has not yet been 
found in a retroviral genome. The three human ras proto-onco-
genes, H-, K-, and N-ras, code for similar proteins (termed p21 
proteins for their molecular mass of 21 kilodaltons) involved in 
conveying growth-factor signals from the plasma membrane to the 
nucleus. In the development of cancer, alterations in p21, .. expres-
sion or activity lead to uncontrolled proliferation, altered cell sur-
face antigen expression, altered cell morphology, and enhanced 
invasiveness. 
In human melanoma, ras oncogene activation is known to be 
associated with point mutations at codons 12, 13, or 61 that cause 
amino acid substitutions. Despite several studies of the problem it is 
not clear whether ras activation is an early event in the development 
of melanoma, a possible cause, or a later event that occurs during 
malignant progression. To address this issue, Ball et al (p. 285) 
studied 100 human melanomas from all stages of malignant pro-
gression. Melanoma DNA was amplified around the 12th, 13th, 
and 61st codons of H-, K-, and N-ras by the polymerase chain 
reaction and checked for the presence of single base pair mutations 
at these codons. The authors found that 36 of the 100 melanomas 
contained ras mutations and that 25 of the 36 cases had mutations at 
the 61st codon ofN-ras. None of the level I and 19% of the level II 
melanomas contained ras mutations, whereas 45% of the level III, 
IV, and V melanomas had mutated ras. Ras mutations occurred in 
48% of recurrent and metastatic tumors. Moreover, 56% of the 
primary tumors from continuously sun-exposed skin had ras muta-
tions compared to 21 % of tumors from intermittently or non - sun-
exposed sites. From these data the authors speculate that ras muta-
tion occurs as a later event in melanoma malignant progression and 
occurs mo:e commonly in melanomas from continuously sun-
exposed skill. The data suggest that the mutations do not lead to the 
developm~nt of melanoma at its initial stage but may be involved in 
the behaVIOr of the tumor once it is established and may affect its 
propensity to metastasize. 
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A Method for Producing Polyclonal Antibodies Against Poorly Antigenic or Closely Related Proteins 
Without Purifying the Protein 
Tyrosinase is the prototype of a family that are involved in deter-
mining the type of pigment synthesized in skin and hair. Members 
of the tyrosinase family of proteins have similar amino acid se-
quences and structures. Therefore, it is not surprising that antibod-
ies generated against one member of the tyrosinase family often 
react with other members of the family. In fact, it has been quite 
difficult to generate antibodies against tyrosinase, perhaps because 
other members of the family are more abundant and immunogenic. 
Bouchard et al (p. 291) have devised a general method to generate 
specific antibodies against individual members of the tyrosinase 
family . 
These investigators transfected the gene encoding human tyro-
sinase into mouse fibroblasts and then used the transfected fibro-
blasts, which now expressed human tyrosinase, a foreign protein, to 
immunize syngeneic mice. Because the only foreign protein in the 
immunizing cells was the tyrosinase expressed by the transfected 
cells, it was hoped that the mice would make antibody against this 
protein alone. The mice generated a strong and specific antibody 
response against human tyrosinase. This approach provides a gen-
eral method to produce specific antibodies against tyrosinase as well 
as against other proteins that are members of closely related families 
of molecules. 
c{os: A Regulatory Molecular Switch Turned on by Sun Exposure? 
Although it is clear that habitual sun exposure is involved in the 
development of non-melanoma skin cancer, the mechanisms are not 
clear. It is known that ultraviolet radiation (UVR) is mutagenic, and 
skin cancers commonly contain mutations in key proto-oncogenes, 
leading to activation of the oncogenes, or in tumor suppressor 
genes, causing inactivation of the tumor suppressor gene protein 
products, and these changes can contribute to the development of 
tumors. Also, overexpression of proto-oncogenes is associated with 
malignant transformation both in villo and ill vitro. In this issue, 
Roddey and co-workers (p. 296) report the effect of a single moder-
ately erythemogenic dose of solar-stimulated UVR on the expres-
sion of two proto-oncogenes, c-fos and c-Ha-ras, in normal intact 
human epidermis. Studies using in situ hybridization to look for c-fos 
mRNA in epidermis show that c-fos mRNA transcripts, normally 
detectable in the basal, or proliferative, compartment of the epider-
mis (Basset-Seguin et al,j'Invest DermatoI94:418-422, 1990), are 
greatly increased approximately one hour after UVR, whereas 
c-Ha-ras transcripts are undetectable in both irradiated and control 
skin. The data build upon an earlier finding by the same group that 
UVR induces c-fos expression in human keratinocytes in vitro (Gar-
myn et ai, j Invest DermatoI99:743-748, 1992), and are consistent 
with the idea that c-fos may be a "master switch" that initiates 
cellular responses to numerous environmental signals. Although 
c-fos expression returned to basal levels within 24 h after the single 
exposure to UVR used in this study, it is tempting to speculate that 
repeated exposures might lead to continuous over-expression of the 
proto-oncogene or perhaps to increased inducibility after UVR, 
consistent with earlier in lIitro studies by this group with keratino-
cytes derived from photodamaged skin. Such dysregulation, what-
ever its molecular basis, might facilitate malignant transformation. 
Overall, this study highlights the utility of molecular biology tech-
niques in deciphering the complex process of photocarcinogenesis 
in human skin. 
Loss of a Region of Chromosome 9: A Defect in a Rare Syndrome that May Apply to Skin Cancer 
in General 
One of the most powerful hypotheses in the molecular genetics of 
cancer was proposed by A. Kudson in the early 1970s (Proc Natl Acad 
Sci USA 68:820-823, 1971). Reasoning from studies on the epi-
demiology of retinoblastoma, Knudson proposed that dominantly 
inherited cancers could be explained by recessive loss of function 
mutations of both alleles. According to this theory, affected indi-
viduals with familial cancer syndromes are predisposed because one 
allele is already abnormal, and somatic mutation or deletion of the 
remaining allele on the homologous chromosome leads to develop-
ment of cancer. Application of this hypothesis to the study of basal 
cell carcinomas (BCCs) has led to the mapping of a dominantly 
inherited syndrome, the nevoid basal cell carcinoma syndrome, to a 
specific location on chromosome 9 called 9q22-31. The high fre-
quency of9q loss in sporadic and familiar BCCs reported by Galiani 
et al (Cell 69:111- 117, 1992) and confirmed by Quinn et al in this 
issue (p. 300) suggests that an unidentified gene in this part of the 
chromosome is behaving like a tumor-suppressor gene and that 
inactivation of both alleles is important in development of BCe. 
The mapping of a second dominantly inherited disorder, the Fergu-
son-Smith syndrome, to the same region on chromosome 9 as the 
gene for the nevoid basal cell carcinoma syndrome is of considerable 
interest because it raises the possibility that this region of chromo-
some 9 may contain more than one gene involved in skin cancer. In 
this issue, Quinn et al have addressed this question by examining the 
frequency and pattern of loss of chromosome 9 alleles both in spo-
radic BCCs and in squamous cell neoplasms of the skin. Using a 
combination of Southern blot and microsatellite analysis, they 
found that loss of chromosome 9q occurred in both types of non-
melanoma skin cancers. They found different patterns of 9q loss in 
BCCs and SCCs and also found that 9p was lost in SCCs but not in 
BCCs, raising the interesting possibility that the targets for allelic 
deletion on chromosome 9 in BCCs and SCCs may not be the same. 
These studies show that chromosome changes found in rare syn-
dromes may elucidate general mechanisms involved in common 
skin cancers. 
ERRATUM 
Two errors appeared in Peter Petzelbauer, Dagmar Fodinger, Kiemens Rappersberger, Beatrix 
Vole Platzer, and Klaus Wolff: CD68 positive epidermal dendritic cells, j Invest Dermatol 
101:256-261,1993. In the abstract, " ... as a link between CD1a+jCD68+jBG+ Langer-
hans cells ... " should read "CD1a+/CD68-/BG+ Langerhans cells." In Results, page 
258, " ... All CD68+ cells were unreactive for anti CDlb, CDllc, CD3, .. . " should read 
" ... CD1b, CDlc, CD3 ... " The authors apologize for these errors. 
